NCT03443674View on ClinicalTrials.gov

Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Peritoneal Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 18, 2018

Primary Completion Date

May 30, 2021

Study Completion Date

August 26, 2021

Conditions
Peritoneal Malignancies
Interventions
DRUG

SCB-313

Lyophilized powder in a single-use vial

Trial Locations (5)

2170

Liverpool Hospital, Liverpool

2500

Southern Medical Day Care Centre, Wollongong

2800

Orange Health Service, Orange

4224

John Flynn Private Hospital, Tugun

5042

Flinders Medical Centre, Bedford Park

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY